BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Partnering to Improve Standard of Care, Provide Turnkey Solutions in Plant-Based Medicine

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is working with doctors as well as government and university research centers to reduce the variations in treatment plans and trials. The company, which has developed and uses dose-measuring internet-of-things (“IoT”) devices to collect HIPPA-compliant data to improve future medical treatments, is guided by the need to transform patient care. Key to this focus is utilizing big data and AI to reshape how the world understands plant-based medicine. A recent article reads, “RYAH partners with doctors to improve the standard of care for patients and researchers to provide a complete turnkey solution for clinical trials to be compliant and standardized. Retailers and product suppliers also benefit from RYAH’s suite of dose-control products, generating recurring revenue streams and strengthening their product offerings. RYAH is working to remove any unnecessary obstacles and maintain a low entry barrier for dispensaries and smaller partners.”

To view the full article, visit https://ibn.fm/s39PA

About RYAH Group Inc.

RYAH is a connected device, and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries, pharmaceutical companies, and licensed processors (“LPs”) to monitor and manage formulation effects on patient and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information about the company, please visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH 

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: Stock Spotlights

Recent Posts

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting Control

Quantum BioPharma (NASDAQ: QNTM) announced the results of its Nov. 10, 2026, annual general and…

1 day ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Publishes Phase 1a Glioblastoma Data, Advances LP-184 Combination Therapy Toward Phase 1b/2a Trial

Lantern Pharma (NASDAQ: LTRN) and its wholly owned subsidiary, Starlight Therapeutics, announced the publication of…

2 days ago

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Signs Four-Year Exclusive Distribution Agreement for GelrinC (R) in Israel

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced…

3 days ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Files Supplement to Shareholder Meeting Materials Clarifying Share Consolidation Terms

Quantum BioPharma (NASDAQ: QNTM) announced that it has filed a supplement to its Sept. 28,…

6 days ago

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Builds Long-Term Value Through Strategic Integration

Earth Science Tech (OTCQB: ETST), a diversified holding company operating across healthcare, pharmacy, technology, telemedicine,…

7 days ago

BioMedNewsBreaks – Why Adaptogenics Health Corp. (CSE: ADPT) Is ‘One to Watch’

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…

7 days ago